Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034925.xml
Download PDF
Hamostaseologie 2017; 37(04): 237
DOI: 10.1055/s-0037-1619835
DOI: 10.1055/s-0037-1619835
Editorial
Update: Direct oral anticoagulants (DOAC) – their use and clinical management remain a challenge
Authors
Further Information
Publication History
received:
18 September 2017
accepted:
19 September 2017
Publication Date:
28 December 2017 (online)
-
References
- 1 Voigtlaender M, Langer F. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism – what do we know so far?. Hämostaseologie 2017; 37: 241-255.
- 2 Lindhoff-Last E. Direct oral anticoagulants – Management of emergency situations – Rationale and design of the RADOA-registry. Hämostaseologie 2017; 37: 257-266.
- 3 Koscielny J, Rosenthal C, von Heymann C. Update on direct oral anticoagulants: perioperative “switching”, drug interactions and persistence. Hämostaseologie 2017; 37: 267-275.
- 4 Benetos G, Bonou M, Toutouzas K, Diamantopoulos P, Viniou N, Barbetseas J. Advances in antico-Prof. Dr. Edelgard Lindhoff-Last Cardioangiology Center Bethanien Hospital (CCB), CCB Vascular Center, CCB Coagulation Center, CCB Coagulation Research Center, Frankfurt, Germany agulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation. Hämostaseologie 2017; 37: 277-285.
- 5 Kücükköylü S, Rump LC. Update Direct oral anticoagulants – use in patients with chronic kidney disease with or without dialysis. Hämostaseologie 2017; 37: 286-294.
- 6 Gosselin RC, Douxfils J, Adcock D. Clinical perls: Laboratory assessment of direct oral anticoagulants. Hämostaseologie 2017; 37: 295-301.
- 7 Göndör G, Stöllberger C. Pulmonary embolism four days after interruption of therapy with rivaroxaban. Hämostaseologie 2017; 37: 302-306.
- 8 Konstantinides SV. The risks of interrupting anticoagulation. Hämostaseologie 2017; 37: 239-240.